成人惡性膠質瘤治療市場規模、佔有率和成長分析：按療法、膠質瘤類型、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球成人惡性膠質瘤治療市場價值為 25.2 億美元，預計到 2025 年將成長至 27.5 億美元，到 2033 年將成長至 55.2 億美元，在預測期（2026-2033 年）內複合年成長率為 9.12%。

全球成人膠質瘤治療市場涵蓋了成人高級別星狀細胞瘤的藥物、生技藥品和創新療法的收入。膠質母細胞瘤五年存活率持續偏低，顯示新療法的需求依然強勁。儘管Temozolomide和放射療法曾是傳統療法的主導，但近年來Bevacizumab和腫瘤治療電場（TTF）等療法的出現，反映了治療方向正向標靶治療和基於醫療設備的療法轉變。分子譜分析和免疫療法的融合使得個人化治療方案成為可能，臨床醫生可以根據EGFRvIII和IDH1等特定基因突變來客製化治療方案。此外，人工智慧驅動的精準醫療正在加速市場成長，並透過整合基因組分析和影像分析來改善患者預後，從而最佳化治療選擇、加速適應性臨床試驗並最佳化以富含生物標記的候選藥物研發管線。

全球成人惡性膠質瘤治療市場按治療方法、膠質瘤類型、分銷管道、最終用戶和地區進行細分。依治療方法分類，市場分為化療（包括替Temozolomide和CCNU）、標靶治療（如Bevacizumab）、腫瘤電場療法（TTFields）、免疫療法和基因療法。依膠質瘤類型分類，市場分為多形性膠質母細胞瘤（GBM）、間變性星狀細胞瘤和瀰漫性內源性腦橋膠質瘤（DIPG）。依分銷管道分類，市場分為醫院藥房和專科藥房。依最終用戶分類，市場分為神經腫瘤中心和醫院。按地區分類，市場分析涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

全球成人惡性膠質瘤治療市場成長要素

個人化醫療的進步正顯著推動全球成人惡性膠質瘤治療市場的發展。個人化醫療能夠根據腫瘤的特定分子特徵量身訂做治療方案。這種個人化治療不僅改善了臨床療效，還提高了患者的生活品質，增強了醫療專業人員和保險公司的信心。這種日益成長的接受度促使更多人使用先進的膠質瘤治療方案，並推動製藥公司加強研發，拓展標靶治療的範圍。這些趨勢促進了產學合作，加速了知識轉移，激發了創新臨床試驗設計的湧現，並進一步推動了市場成長。

全球成人惡性膠質瘤治療市場面臨的限制因素

全球成人惡性膠質瘤治療市場面臨許多挑戰，主要原因在於先進治療方案的高成本。醫療支付者通常會權衡預算影響與這些創新療法帶來的額外臨床效益。新藥的高昂成本以及複雜的給藥方案，對醫療系統構成重大障礙，尤其是在資源匱乏的環境中。因此，臨床醫生可能會選擇價格較低廉的舊療法，阻礙新藥的市場滲透。這些成本問題也使報銷談判更加複雜，最終導致新藥上市延遲，限制整體成長，同時也阻礙了對旨在促進更廣泛應用的大規模臨床計畫的投資。

成人惡性膠質瘤治療的全球市場趨勢

全球成人惡性膠質瘤治療市場正經歷著向個人化免疫療法的顯著轉變，這主要得益於我們對膠質瘤細胞分子特徵認知的不斷深入。業界領導者正加大針對個別患者特徵量身定做的適應性疫苗平台以及與新型查核點抑制劑聯合治療的投資。這一趨勢的推動因素包括：越來越多的證據表明免疫調節能夠提高存活率；以及患者對微創、高標靶性療法的需求不斷成長。因此，各公司正在調整開發平臺，專注於生物標記主導的候選藥物，並與學術機構建立合作關係，以加速創新療法的轉化開發。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球成人惡性膠質瘤治療市場規模：依治療類型分類

• 化療（Temozolomide，CCNU）
• 標靶治療（Bevacizumab）
• 腫瘤電場治療（TTFields）
• 免疫療法
• 基因治療

全球成人惡性膠質瘤治療市場規模：依膠質瘤類型分類

• GBM（多形性膠質母細胞瘤）
• 退行性星細胞瘤
• 瀰漫性內源性腦橋膠質瘤

全球成人惡性膠質瘤治療市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房

全球成人惡性膠質瘤治療市場規模：依最終用戶分類

• 神經腫瘤中心
• 醫院

全球成人惡性膠質瘤治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novocure（Optune/TTFields）
• Roche（Avastin/Bevacizumab）
• Bristol Myers Squibb
• Merck & Co.
• AstraZeneca
• DelMar Pharmaceuticals
• Tocagen（Mustang Bio）
• Northwest Biotherapeutics（DC-Vax）
• Immunomedics（Gilead）
• DNAtrix（Oncobiologics）
• Nuvation Bio
• Kintara Therapeutics（DelMar）
• Humanigen Inc.
• Hepion Pharmaceuticals
• Black Diamond Therapeutics
• Forma Therapeutics
• Relay Therapeutics
• Kymera Therapeutics
• Prelude Therapeutics
• G1 Therapeutics

結論與建議

Global Adult Malignant Glioma Therapeutics Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.75 Billion in 2025 to USD 5.52 Billion by 2033, growing at a CAGR of 9.12% during the forecast period (2026-2033).

The global market for adult malignant glioma therapeutics encompasses revenue generated from pharmaceuticals, biologics, and innovative treatment regimens targeting high-grade astrocytic tumors in adults. The persistent low five-year survival rate for glioblastoma ensures sustained demand for novel therapies. While temozolomide and radiation have traditionally dominated, recent advancements like bevacizumab and tumor-treating fields reflect a shift towards targeted and device-based options. The convergence of molecular profiling with immunotherapy facilitates personalized treatment plans, enabling clinicians to align therapies with specific genetic alterations such as EGFRvIII and IDH1. Furthermore, AI-driven precision medicine enhances treatment selection by integrating genomic profiling and imaging analytics, fostering adaptive clinical trials and optimizing drug pipelines focused on biomarker-rich candidates, thereby accelerating market growth and improving patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adult Malignant Glioma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Adult Malignant Glioma Therapeutics Market Segments Analysis

The global adult malignant glioma therapeutics market is segmented based on treatment type, glioma type, distribution channel, end-user, and region. By treatment type, the market is categorized into Chemotherapy (including Temozolomide and CCNU), Targeted Therapy (such as Bevacizumab), Tumor Treating Fields (TTFields), Immunotherapy, and Gene Therapy. Based on glioma type, the market is divided into Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma, and Diffuse Intrinsic Pontine Glioma (DIPG). By distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is classified into Neuro-Oncology Centers and Hospitals. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Adult Malignant Glioma Therapeutics Market

The Global Adult Malignant Glioma Therapeutics market is significantly propelled by the advancement of personalized medicine, which tailors treatments to specific molecular characteristics of tumors. This customization not only enhances clinical outcomes but also boosts the quality of life for patients, fostering greater confidence among healthcare providers and insurers alike. This increased acceptance paves the way for more frequent prescriptions of advanced glioma therapies, prompting pharmaceutical companies to intensify their research efforts and expand the range of targeted therapies available. Such developments promote collaborations between academia and industry, facilitating faster knowledge transfer and stimulating innovative clinical trial designs, further driving market growth.

Restraints in the Global Adult Malignant Glioma Therapeutics Market

The Global Adult Malignant Glioma Therapeutics market faces significant challenges primarily due to the high costs associated with advanced treatment options. Healthcare payers often weigh the budgetary impact against the incremental clinical benefits of these innovative therapies. The expense of novel agents, coupled with complex administration requirements, presents substantial obstacles for healthcare systems, particularly in resource-limited settings. Consequently, clinicians may opt for older, more affordable treatment regimens, hindering the market penetration of newer drugs. This financial sensitivity also complicates reimbursement discussions, ultimately delaying market access and constraining overall growth, while simultaneously deterring investment in large-scale clinical programs that promote wider adoption.

Market Trends of the Global Adult Malignant Glioma Therapeutics Market

The Global Adult Malignant Glioma Therapeutics market is witnessing a significant shift towards personalized immunotherapy, driven by advancements in understanding the molecular signatures of glioma cells. Industry players are increasingly investing in adaptive vaccine platforms and novel checkpoint inhibitor combinations tailored to individual patient profiles. This trend is fueled by emerging evidence linking immune modulation to improved survival rates, alongside patient demand for less invasive, precisely targeted treatment options. Consequently, companies are restructuring their R&D pipelines to emphasize biomarker-led candidates and are fostering collaborative ecosystems with academic institutions, thereby accelerating the translational development of innovative therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Adult Malignant Glioma Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy (Temozolomide, CCNU)
• Targeted Therapy (Bevacizumab)
• Tumor Treating Fields (TTFields)
• Immunotherapy
• Gene Therapy

Global Adult Malignant Glioma Therapeutics Market Size by Glioma Type & CAGR (2026-2033)

• Market Overview
• GBM (Glioblastoma Multiforme)
• Anaplastic Astrocytoma
• Diffuse Intrinsic Pontine Glioma

Global Adult Malignant Glioma Therapeutics Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Adult Malignant Glioma Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Neuro-Oncology Centers
• Hospitals

Global Adult Malignant Glioma Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment Type, Glioma Type, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment Type, Glioma Type, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Glioma Type, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Glioma Type, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Glioma Type, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novocure (Optune/TTFields)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Avastin/Bevacizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DelMar Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tocagen (Mustang Bio)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Northwest Biotherapeutics (DC-Vax)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunomedics (Gilead)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNAtrix (Oncobiologics)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuvation Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kintara Therapeutics (DelMar)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Humanigen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Black Diamond Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Forma Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Relay Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prelude Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• G1 Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations